From better-understanding how to improve response rates in multiple myeloma patients to identifying why some patients with other types of cancer are...
Myeloma NZ
Research Review: Multiple Myeloma – Issue 28
Issue 28 of Multiple Myeloma Research Review. Highlights include:Â Elotuzumab monotherapy for smouldering MM Thereapetuc vulnerability of MM to...
Registry could be ‘invaluable’ for tracking long-term CAR T-cell therapy outcomes
The Center for International Blood and Marrow Transplant Research, through an alliance with Novartis, aims to track the long-term outcomes of...
Expert Evaluates Evolving Options in Newly Diagnosed Myeloma
Transplant remains the standard of care for eligible patients with newly diagnosed multiple myeloma, although the optimal induction regimen and...
Advances in myeloma treatments, diagnostics have specialists ‘talking about cure’
A decade ago, patients with newly diagnosed multiple myeloma typically survived 3 to 5 years. However, the development of highly effective therapies...
An exciting treatment for the multiple myeloma community
A leading international consultant haematologist in the treatment of multiple myeloma, Professor Saad Z. Usmani, Chief of Plasma Cell Disorders...
Scientists stumble on promising agent for incurable cancer
Kiwi researchers have stumbled upon what could be a promising agent against an incurable blood cancer. Based on just-published findings, Otago...
FDA Commissioner Voices Concerns About CAR T-Cell Therapy Payment
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, expressed concern in October over the price of chimeric antigen receptor...
New study sheds light on how CAR T cell therapy works
Cancer remains the second-leading cause of death in the United States. This year, an estimated 1.7 million new cases will be diagnosed, with nearly...
Newsletter: October 2018
Greetings. Spring is in the air and the end of the year is fast approaching. Save the Date  The final patient seminar and end of year function...
FDA Approves NGS-Based Test for Patients With ALL or MM
The U.S. Food and Drug Administration (FDA) has authorized the next-generation sequencing (NGS)–based clonoSEQ assay for the measurement of minimal...
Bisphosphonates for Patients Diagnosed With Multiple Myeloma
Clinical Question Among patients with multiple myeloma, is bisphosphonate therapy associated with lower rates of mortality, vertebral fractures,...